VIC-1911

DRUG2 trials

Sponsors

Vitrac Therapeutics, LLC, Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Conditions

Advanced Non-small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

TerminatedNCT05374538

Vitrac Therapeutics, LLCNon-small Cell Lung Cancer

Start: 2022-11-09End: 2023-08-26Updated: 2025-05-01

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.Advanced Non-small Cell Lung Cancer

Start: 2022-09-21End: 2024-04-24Target: 72Updated: 2023-06-15

Related Papers

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-015 citations

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

ACS Omega2024-05-033 citations

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of <i>KRAS G12C</i>-mutant non–small-cell lung cancer.

Journal of Clinical Oncology2023-06-015 citations